98 filings
Page 2 of 5
8-K
fn1uuxhr61
7 Nov 23
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:10pm
8-K
ba8 3vcqnv7aotansfqp
23 Oct 23
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
7:45am
8-K/A
mrqm98j02zb4k9 ia78d
18 Oct 23
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
4:46pm
8-K
9ejvxuqeepa
17 Oct 23
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
7:33am
8-K
9uj1oh03
10 Oct 23
Olema Oncology Announces Expansion of Collaboration
7:17am
D
7khgh7 jrzjhi11bm36
14 Sep 23
$130.00 mm in equity, sold $130.00 mm, 12 investors
4:14pm
8-K
6o0v 6783
5 Sep 23
Olema Oncology Announces Combined Financing for Up to $180 Million
7:39am
8-K
wy8a 003457
8 Aug 23
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
kr6ys3xf522p
21 Jun 23
Submission of Matters to a Vote of Security Holders
4:31pm
8-K
ca7mwt5z kt0sbflz
11 May 23
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
9:24am
8-K
t06e5a znpa5qmq6luc4
9 May 23
Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
ARS
i21x6ub kmpzaz
28 Apr 23
Annual report to shareholders
4:25pm
DEFA14A
sikpa1x s2ke1n
28 Apr 23
Additional proxy soliciting materials
4:06pm
8-K
r7m6ma carh0
10 Mar 23
Regulation FD Disclosure
4:17pm
424B5
0f8cr5zgh2ovmqk8j
9 Mar 23
Prospectus supplement for primary offering
4:51pm
S-8
5mrq b95mrnx
9 Mar 23
Registration of securities for employees
4:33pm